About Eligo Bioscience
Eligo Bioscience is a company based in Paris (France) founded in 2014 by David Bikard and Xavier Duportet. Eligo Bioscience has raised $52.26 million across 7 funding rounds from investors including Khosla Ventures, Bpifrance and European Union. Eligo Bioscience offers products and services including GEM Platform. Eligo Bioscience operates in a competitive market with competitors including eGenesis, Beam Therapeutics, Korro Bio, Insmed and Scribe Therapeutics, among others.
- Headquarter Paris, France
- Founders David Bikard, Xavier Duportet
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Eligo Bioscience
-
Annual Revenue
$1.92 M (USD)-16as on Dec 31, 2021
-
Net Profit
-$5.16 M (USD)-183as on Dec 31, 2021
-
EBITDA
-$7.47 M (USD)-120as on Dec 31, 2021
-
Total Equity Funding
$52.26 M (USD)
in 7 rounds
-
Latest Funding Round
$5 M (USD), Grant
May 13, 2025
-
Investors
Khosla Ventures
& 5 more
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Eligo Bioscience
Eligo Bioscience offers a comprehensive portfolio of products and services, including GEM Platform.
Platform for in vivo editing of microbiome genes to influence health.
Funding Insights of Eligo Bioscience
Eligo Bioscience has successfully raised a total of $52.26M across 7 strategic funding rounds. The most recent funding activity was a Grant round of $5 million completed in May 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 7
- Last Round Grant — $5.0M
-
First Round
First Round
(08 Jul 2015)
- Investors Count 6
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| May, 2025 | Amount | Grant - Eligo Bioscience | Valuation |
investors |
|
| Nov, 2023 | Amount | Series B - Eligo Bioscience | Valuation | Sanofi Ventures | |
| Mar, 2022 | Amount | Grant - Eligo Bioscience | Valuation |
investors |
Investors in Eligo Bioscience
Eligo Bioscience has secured backing from 6 investors, including venture fund and institutional investors. Prominent investors backing the company include Khosla Ventures, Bpifrance and European Union.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Life-Sciences focused Early stage Corporate VC Firm investing in the US
|
Founded Year | Domain | Location | |
|
Early-stage startups are funded by this venture capital firm.
|
Founded Year | Domain | Location | |
|
Tech & Life Sciences focused stage agnostic VC firm investing in Europe, Asia & the US
|
Founded Year | Domain | Location |
Investments & Acquisitions by Eligo Bioscience
Financial Statements - Eligo Bioscience
Eligo Bioscience Comparisons
Competitors of Eligo Bioscience
Eligo Bioscience operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as eGenesis, Beam Therapeutics, Korro Bio, Insmed and Scribe Therapeutics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Gene transplantation platform for humanizing pig cells is developed.
|
|
| domain | founded_year | HQ Location |
Developer of gene therapy using CRISPR base editing to treat diseases
|
|
| domain | founded_year | HQ Location |
RNA-editing technologies are provided for precision medicine applications.
|
|
| domain | founded_year | HQ Location |
Developer of small molecule inhibitors for rare lung diseases
|
|
| domain | founded_year | HQ Location |
A CRISPR-based gene-editing platform is developed for therapeutic applications.
|
|
| domain | founded_year | HQ Location |
New genome engineering technology is provided for treating multiple diseases.
|
Frequently Asked Questions about Eligo Bioscience
Eligo Bioscience was founded in 2014 and raised its 1st funding round 1 year after it was founded.
Eligo Bioscience is headquartered in Paris, France.
Xavier Duportet is the current CEO of Eligo Bioscience. They have also founded this company.
Eligo Bioscience is a funded company, having raised a total of $52.26M across 7 funding rounds to date. The company's 1st funding round was a Grant of $55.68K, raised on Jul 08, 2015.
Annual revenue of Eligo Bioscience is $1.92M as on Dec 31, 2021.
Eligo Bioscience was founded in 2014 in Paris, France, within the biotechnology sector. In vivo gene editing tools are provided to modify the microbiomes genetic composition. Diseases influenced by particular bacterial genes are targeted through this platform. Interactions between microbial communities and the host immune system are addressed in therapeutic applications. Operations focus on advancing microbiome-based interventions for health conditions.
Eligo Bioscience's top competitors include eGenesis, Tessera Therapeutics and Korro Bio.
Eligo Bioscience offers GEM Platform.
Eligo Bioscience has 6 investors. Key investors include Khosla Ventures, Bpifrance, European Union, Sanofi Ventures, and Seventure Partners.